MedWatch

Snipr Biome to collaborate with US cancer hospital

The Danish company will examine the effect of new CRISPR therapies as a treatment for immune therapy side effects alongside the MD Anderson Cancer Center.

Snipr Biome CEO Christian Grøndahl | Photo: EY / PR

Biotech company Snipr Biome has found a partner to help develop new treatments using CRISPR technology, which targets the human microbiome.

The company has teamed up with renowned US cancer hospital MD Anderson Cancer Center, which is associated with the University of Texas. Snipr Biome will work with a research department at the hospital called PRIME-TR.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs